NodThera News and Activities

View the org chart displaying its 16 main executives

Most searched biographies at NodThera

• Geoff Mcdonough, Chief Executive Officer and Director
• Alex Pasteur, Director
• Jim Trenkle, Director

Popular executive movements at NodThera

• Geoff Mcdonough, who was Independent Director, is promoted to Chief Executive Officer and Director  (posted on February 7 2026).
• Geoff Mcdonough has joined the company as Independent Director  (posted on December 18 2025).
• Chris Guiffre has joined the company as Chief Financial Officer  (posted on October 29 2025).

Click here to view some more movements at NodThera

Create your alert
to follow the executive moves at NodThera.

NodThera has 2,415 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
• Boundless Bio will change its company name to Serapha Bio on Dec 31, 2026. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by NodThera

• NodThera Announces the Publication and Presentation of Cardiometabolic Clinical Data Supporting the Potential of Ruvonoflast to Treat Inflammation at the Source - Nodthera
• NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress - Nodthera
• NodThera to Participate in April Investor Conferences - Nodthera
• NodThera to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Nodthera
• NodThera Announces Appointment of Chris Guiffre, J.D., M.B.A., as Chief Financial Officer - Nodthera
• NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination with a GLP-1 Receptor Agonist - Nodthera
• NodThera Announces Appointment of Elisabeth Björk as Board Member - Nodthera
• NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 - Nodthera
• NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer - Nodthera
• NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor - Nodthera
• View more press releases Close

Social media about NodThera

• NodThera on Wikipedia, Google News & Yahoo Finance
• NodThera on LinkedIn, X (Twitter) & YouTube